Nikhil I. Khushalani
Expertise in
11
conditions

Dr. Nikhil I. Khushalani

Oncology
Moffitt Cancer Center, Richard M. Schulze Family Foundation Outpatient Center At McKinley Campus
10920 McKinley Dr, 
Tampa, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
11
conditions
Moffitt Cancer Center, Richard M. Schulze Family Foundation Outpatient Center At McKinley Campus
10920 McKinley Dr, 
Tampa, FL 

Overview

Nikhil Khushalani is an Oncologist practicing medicine in Tampa, Florida.

Dr. Khushalani is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Neuroendocrine Tumor, and Metastatic Brain Tumor.

He is actively involved in clinical research, co-authoring 144 peer reviewed articles and participating in 18 clinical trials. Dr. Khushalani is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in NY

Languages Spoken

English
Hindi
Marathi
Sindhi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Moffitt Cancer Center, Richard M. Schulze Family Foundation Outpatient Center at McKinley Campus
10920 McKinley Dr, Tampa, FL 33612

Additional Areas of Focus

Dr. Khushalani has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: Safety and Biomarker Analysis
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: Safety and Biomarker Analysis
Enrollment Status: Recruiting
Publish Date: June 25, 2026
Intervention Type: Drug
Study Drug: Cemiplimab
Study Phase: Phase 1
A Phase II Study of High Dose Bolus IL2 in Combination With Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
A Phase II Study of High Dose Bolus IL2 in Combination With Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drugs: Interleukin-2, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Biological, Drug
Study Drugs: Ipilimumab, Nivolumab, Prednisone, Tacrolimus
Study Phase: Phase 1
Phase 2 Study of Axitinib + Ipilimumab in Advanced Melanoma
Phase 2 Study of Axitinib + Ipilimumab in Advanced Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2026
Intervention Type: Drug
Study Drugs: Ipilimumab, Axitinib
Study Phase: Phase 2
Neoadjuvant Immunotherapy With Intratumoral Tavokinogene Telseplasmid (Tavo) Plus Electroporation in Combination With Intravenous Nivolumab in Patients With Operable Locally- Regionally Advanced Melanoma
Neoadjuvant Immunotherapy With Intratumoral Tavokinogene Telseplasmid (Tavo) Plus Electroporation in Combination With Intravenous Nivolumab in Patients With Operable Locally- Regionally Advanced Melanoma
Enrollment Status: Completed
Publish Date: June 29, 2026
Intervention Type: Device, Drug
Study Drugs: Tavo, Nivolumab
Study Phase: Phase 2
Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma
Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2026
Intervention Type: Drug
Study Drugs: Lenvatinib Oral Product, Pembrolizumab
Study Phase: Phase 2
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2026
Intervention Type: Drug
Study Drugs: LXH254, LTT462, Trametinib, Ribociclib
Study Phase: Phase 2
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2026
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Phase I Study of Escalating Doses of XL888 With Vemurafenib Plus Cobimetinib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
Phase I Study of Escalating Doses of XL888 With Vemurafenib Plus Cobimetinib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: March 02, 2026
Intervention Type: Drug
Study Drugs: XL888, Vemurafenib, Cobimetinib
Study Phase: Phase 1
View 9 Less Clinical Trials

144 Total Publications

Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma.
Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma.
Journal: JAMA dermatology
Published: July 08, 2026
Similar Doctors
Expertise in
30
conditions
Expertise in
30
conditions
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (1.1 miles away)
813-934-6811
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Philippe Spiess is an Oncologist practicing medicine in Tampa, Florida. Dr. Spiess is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Penile Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Penectomy. Dr. Spiess is currently accepting new patients.

Expertise in
55
conditions
Dr. Lubomir Sokol
Hematology | Oncology
Expertise in
55
conditions
Dr. Lubomir Sokol
Hematology | Oncology
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (1.1 miles away)
813-692-4147
Languages Spoken:
English, Czech, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Lubomir Sokol is a Hematologist and an Oncologist practicing medicine in Tampa, Florida. Dr. Sokol is highly rated in 55 conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sokol is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (1.1 miles away)
813-934-6809
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Wade Sexton is an Oncologist practicing medicine in Tampa, Florida. Dr. Sexton is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Orchiectomy. Dr. Sexton is currently accepting new patients.

Frequently Asked Questions about Dr. Nikhil I. Khushalani

How do I make an appointment with Dr. Nikhil I. Khushalani?

You can book an appointment with Dr. Nikhil I. Khushalani by calling their office at 813-676-8946. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Nikhil I. Khushalani a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Nikhil I. Khushalani is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Nikhil I. Khushalani specialize in?

While Dr. Nikhil I. Khushalani is a Oncology, they have specific expertise in Melanoma, Merkel Cell Carcinoma, and Neuroendocrine Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Nikhil I. Khushalani participate in research or clinical trials?

Yes. Dr. Nikhil I. Khushalani has published 144 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Nikhil I. Khushalani's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Nikhil I. Khushalani accept my insurance?

Dr. Nikhil I. Khushalani accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 813-676-8946 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Khushalani's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 49 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile